The estimated Net Worth of John Y Televantos is at least $6.54 Миллион dollars as of 6 November 2015. John Televantos owns over 6,435 units of Balchem stock worth over $4,644,614 and over the last 19 years he sold BCPC stock worth over $1,682,779. In addition, he makes $214,336 as Lead Independent Director at Balchem.
Sign up
John Televantos BCPC stock SEC Form 4 insiders trading
John has made over 8 trades of the Balchem stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 6,435 units of BCPC stock worth $414,478 on 6 November 2015.
The largest trade he's ever made was selling 6,435 units of Balchem stock on 6 November 2015 worth over $414,478. On average, John trades about 858 units every 66 days since 2005. As of 6 November 2015 he still owns at least 28,326 units of Balchem stock.
You can see the complete history of John Televantos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Televantos biography
Dr. John Y. Televantos Ph.D. serves as Lead Independent Director of the Company. Dr. Televantos holds B.S. and Ph.D. degrees in Chemical Engineering from the University of London, United Kingdom. In addition to his experience in the chemical manufacturing industry and management of publicly traded chemical manufacturing entities, Dr. Televantos is also significantly involved in private equity markets and processes involving chemical manufacturing companies. Collectively, these make Dr. Televantos a valuable member of the Board.
What is the salary of John Televantos?
As the Lead Independent Director of Balchem, the total compensation of John Televantos at Balchem is $214,336. There are 9 executives at Balchem getting paid more, with Theodore Harris having the highest compensation of $3,808,410.
How old is John Televantos?
John Televantos is 67, he's been the Lead Independent Director of Balchem since 2010. There are no older and 11 younger executives at Balchem.
What's John Televantos's mailing address?
John's mailing address filed with the SEC is BALCHEM CORPORATION, 5 PARAGON DRIVE, MONTVALE, NJ, 07645.
Insiders trading at Balchem
Over the last 21 years, insiders at Balchem have traded over $37,143,279 worth of Balchem stock and bought 47,350 units worth $1,702,145 . The most active insiders traders include Dino A Rossi, Frank Fitzpatrick и David F Ludwig. On average, Balchem executives and independent directors trade stock every 36 days with the average trade being worth of $2,396,094. The most recent stock trade was executed by Gunsteren Job Leonard Van on 31 July 2024, trading 7,750 units of BCPC stock currently worth $462,288.
What does Balchem do?
founded in 1967, balchem provides state-of-the-art solutions and the finest quality products for a range of industries worldwide. our company consists of four business segments: human nutrition & health; specialty products; animal nutrition and health and industrial products. balchem employs approximately 1,000 people worldwide who are engaged in many diverse activities, developing our company into chosen market leadership positions. visit our website at www.balchem.com to learn more about us and the exciting opportunities we have available!
What does Balchem's logo look like?
Complete history of John Televantos stock trades at Balchem
Balchem executives and stock owners
Balchem executives and other stock owners filed with the SEC include:
-
Theodore Harris,
Chairman of the Board, President, Chief Executive Officer -
Theodore L. Harris,
Chairman, CEO & Pres -
Martin Bengtsson,
Chief Financial Officer -
Scott Mason,
Vice President of Manufacturing and Supply Chain and Vice President and General Manager, Industrial Products -
William Backus,
Chief Accounting Officer -
Mark Stach,
General Counsel, Secretary -
Carl Martin Bengtsson,
CFO & Treasurer -
James C. Hyde,
Sr. VP and GM of Human Nutrition & Health -
Mark A. Stach,
Gen. Counsel & Corp. Sec. -
John Televantos,
Lead Independent Director -
Daniel Knutson,
Independent Director -
Matthew Wineinger,
Independent Director -
Perry Premdas,
Independent Director -
David Fischer,
Independent Director -
Paul Coombs,
Independent Director -
Joyce Lee,
Independent Director -
Dino A Rossi,
President and CEO -
Edward Mcmillan,
Director -
Matthew David Houston,
General Counsel, Secretary -
Frank Fitzpatrick,
Corp Controller & Treasurer -
Mary Theresa Coelho,
Chief Financial Officer -
Monica Vicente,
-
Olivier Rigaud,
-
Elaine R Wedral,
Director -
Richard Allen Bendure,
Chief Operating Officer -
Francis X Mcdermott,
Director -
Paul H Richardson,
VP Research and Development -
Dana E. Putnam,
VP and General Manager -
Cruce Patricia Siuta,
Vice President Technology -
Israel Sheinberg,
Director -
Winston A Samuels,
Vice President/GM Encapsulates -
Hoyt Jr Ammidon,
Director -
Kenneth P Mitchell,
Director -
Robert T Miniger,
VP/Human Resources -
David F Ludwig,
Vice President -
James C Hyde,
Sr. Vice President -
Kathleen B Fish,
-
Frederic Boned,
SVP/GM, Human Nutri. & Health -
Martin Luther Reid,
SVP Chief Supply Chain Officer -
Hatsuki Miyata,
EVP, Gen. Counsel & Secretary -
Gunsteren Job Leonard Van,
SVP and GM, Specialty Products -
Michael Robert Sestrick,
SVP & Chief Technology Officer -
Michael Brent Tignor,
SVP & Chief HR Officer -
Jonathan Harrison Griffin,
SVP & GM, Animal Nutrition